Conditions: Prostate Cancer
Keywords: Prostate Cancer Men Androgen Deprivation Therapy Elderly Geriatric Nutritional supplementation
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 48
Healthy volunteers: no

Brief summary:
This is a study of HMB plus amino acids in older men with prostate cancer starting androgen deprivation therapy (ADT). The investigators hypothesize that the use of this nutritional supplementation will decrease the loss of muscle mass and strength that occurs when men start ADT.

Detailed description:
It is well established that older patients experience age-related loss of muscle mass and function (sarcopenia), presumably due to an imbalance of protein synthesis versus protein breakdown. In addition, studies have shown that men who start on ADT experience increased muscle protein breakdown and decreased synthesis. β-hydroxy-β-methylbutyrate (HMB), a leucine metabolite, has been shown to slow protein breakdown. When HMB is given with arginine and lysine (which support protein synthesis) in randomized trials, researchers have shown that elderly men and women who receive this nutritional supplementation experience improvement in fat-free mass, strength, functionality and protein synthesis when compared with controls. In addition, patients with advanced cancer who experienced weight loss of at least 5% have also been shown to benefit from HMB, with supplementation resulting in a significant increase of fat-free mass when compared to controls. Thus, it seems reasonable that older men with prostate cancer starting on ADT who experience lean muscle loss as a result of aging and ADT, may achieve some benefit from supplementation with HMB as well. Use of HMB in men with prostate cancer has not been reported.

Arms:
arm 1: Standard of care androgen deprivation therapy plus the nutritional supplement HMB + arginine + glutamine (AG) arm 2: Standard of care androgen deprivation therapy

Interventions: intervention 1: Standard of care ADT + (HMB + arginine + glutamine) intervention 2: Standard of care ADT
Intervention descriptions: intervention 1: 1 packet of HMB+arginine+glutamine contains 1.5 g of the amino acid metabolite HMB + 7 g arginine and 7 g glutamine.

Take one packet twice daily for 3 months intervention 2: Patient will receive standard of care androgen deprivation therapy (ADT) alone

Protocol document:
Prot_SAP_000.pdf: 
Protocol Title:  USE OF ß-HYDROXY-ß-METHYLBUTYRATE (HMB) TO COUNTERACT 
LOSS OF MUSCLE MASS AND STRENGTH IN OLDER MEN WITH PROSTATE CANCER 
STARTED ON ANDROGEN DEPRIVATION THERAPY (ADT) 
 
Clinical Trials.gov Number:  NCT01607879 
 
Date:  08/14/15 


(Protocol v3.0, dated 8/14/15) 
 
ADDENDUM 1: Research Protocol 
 
 
 
Medical College of Wisconsin 
 
 
 
USE OF ß-HYDROXY-ß-METHYLBUTYRATE (HMB) TO COUNTERACT LOSS OF 
MUSCLE MASS AND STRENGTH IN OLDER MEN WITH PROSTATE CANCER 
STARTED ON ANDROGEN DEPRIVATION THERAPY (ADT) 
 
 
 
 
 
 
 
 
 
Principle Investigator:   
Kathryn Bylow, MD 
 
 
Co-Investigators: 
 
James Thomas, MD, PhD 
 
 
 
 
Alex Ng, PhD 
 
 
 
 
Robert Prost, PhD 
 
 
 
 
Danny Riley, PhD 
 
 
 
 
Colleen Lawton, MD 
 
 
 
 
William See, MD 
 
 
 
Medical College of Wisconsin 
9200 W. Wisconsin Ave. 
 
 
 
 
 
Milwaukee, WI  53226 
 
 
 
 
 
Phone: (414) 805-4600 
 
 
 
 
 
Fax: (414) 805-4606 


 
2
 
1.  INTRODUCTION 
 
Prostate cancer (PCa) is the second most common cancer in men, primarily affecting older men.  The 
standard treatment for recurrent and metastatic Pca is ADT.  It is also standard of care for men with 
intermediate or high risk localized prostate cancer who plan to get radiation to receive ADT in the neoadjuvant 
and adjuvant setting. It is well established that ADT causes muscle weakness and wasting, osteoporosis, and 
fatigue.  Our preliminary data suggests that older men on ADT have significant physical performance deficits, 
functional impairments, and falls at higher rates than men in the general geriatrics population.  HMB is a 
leucine metabolite which has been shown to decrease the rate of muscle protein breakdown.  When given with 
arginine and lysine or glutamine, HMB has been shown to improve strength, fat-free mass and function in the 
general geriatrics population who are prone to sarcopenia.  Use of HMB and/or amino acid supplementation in 
older men with PCa starting on ADT has not been reported.  We will prospectively: 1) measure the change in 
body composition, strength, physical performance, and falls in older men with PCa starting on ADT, comparing 
those who receive HMB + AG versus those who do not, 2) evaluate the use of MRI and muscle biopsy to 
identify changes in muscle composition and muscle fatiguability that are known to occur in this patient 
population.  We will test the hypothesis that HMB + AG can reduce the adverse change in body composition 
and strength/muscle fatiguability that occur when older men with Pca are started on ADT.  With data obtained 
in this study, a larger randomized study will be 
designed to compare interventions aimed at minimizing 
the adverse affects that occur with ADT initiation. 
 
 
2.  BACKGROUND  
Seventy-five percent of Pca incidence and greater than 
90% of Pca mortality occurs in men aged 65 years or 
older.1  PCa is the second most common cancer in 
American men, with more than 217,000 new cases 
anticipated in 2010.2 Men live with Pca for many years. 
 Once patients develop biochemical recurrence (PSA 
rise) after prostatectomy for local disease, the median 
time to development of distant metastasis in the 
absence of treatment is 8 years and median time to 
death an additional 5 years after development of 
metastases.3  Due to competing comorbidities, a significant number of older men with PCa will die with, not as 
a result of, their disease. In fact, only 39% of men diagnosed with PCa after age 67 die of their disease.4  
Thus, it is extremely important for providers to be aware of potential toxicities of therapy, as men will likely live 
with these side effects for many years. 
 
The standard therapy for metastatic and recurrent Pca is ADT, a potentially toxic therapy.  It is well established 
that ADT can cause significant morbidity, including fatigue, anemia, osteopenia/osteoporosis and decrease in 
muscle mass, occurring as early as 1-3 months after ADT initiation.5-8 Patients on ADT for one year have a 
lower relative muscle mass, reduced upper limb strength, and worse self-reported physical function than those 
not on ADT.9  Increased prevalence of fractures in Pca patients on ADT has also been reported, with a 
positive correlation between number of LHRH agonist doses and fracture risk.10  Because older men are a 
“compromised host” who are already experiencing increased comorbidities, limited life expectancy and loss of 
muscle mass resulting in impaired muscle function associated with aging, they are particularly vulnerable to 
the potential side effects of therapy.  In fact, several of the known toxicities of ADT, including sarcopenia, 
weakness, mobility problems, and fatigue, are part of the classic components of frailty - a geriatrics syndrome 
which imparts significant risk for adverse outcomes including falls, disability, hospitalization, and death.5,11-14  
We have hypothesized that ADT may, indeed, induce frailty in a subset of older men with Pca (Figure 1).15,16  
Despite the known toxicities and lack of survival benefit in many cases, the use of ADT has increased by 27% 
in less than a decade.17   
 
Figure 1. Possible Contribution of ADT to the Development of Frailty 
Aging 
ADT 
Sarcopenia 
Lowered Muscle Power 
Weakness 
Fatigue 
Impaired Mobility 
Low Testosterone 
Anemia 
Low Activity 
Inflammation 
(Lean) Weight Loss 


 
3
It is well established that older patients experience age-related loss of muscle mass and function (sarcopenia), 
presumably due to an imbalance of protein synthesis versus protein breakdown.18,19  In addition, studies have 
shown that men who start on ADT experience increased muscle protein breakdown and decreased 
synthesis.20  β-hydroxy-β-methylbutyrate (HMB), a leucine metabolite, has been shown to slow protein 
breakdown.  When HMB is given with arginine and lysine (which support protein synthesis) in randomized 
trials, researchers have shown that elderly men and women who receive this nutritional supplementation 
experience improvement in fat-free mass, strength, functionality and protein synthesis when compared with 
controls.21,22  In addition, patients with advanced cancer who experienced weight loss of at least 5% have also 
been shown to benefit from HMB, with supplementation resulting in a significant increase of fat-free mass 
when compared to controls.23  Thus, it seems reasonable that older men with Pca starting on ADT who 
experience lean muscle loss as a result of aging and ADT, may achieve some benefit from supplementation 
with HMB as well. 
 
Strength can be defined as the maximal voluntary force generating capacity of a muscle or muscle group (i.e., 
MVC).  Muscle strength is directly related to muscle mass, and in turn, to muscle contractile or fat-free cross-
sectional area (CSA). Muscle CSA in older adults can be measured accurately and non-invasively by magnetic 
resonance imaging (MRI) techniques and much of what we know about sarcopenia comes from such 
studies.24,25  Specific strength is the ratio of MVC/CSA.  A loss of muscle mass, such as from sarcopenia, can 
lead to weakness without a change in specific strength.  A decrease in specific strength would be indicative of 
central activation failure or a change in the intrinsic ability of the muscle to contract (i.e., altered intramuscular 
proteins). 
 
Muscle fatigue can be described as a decrease in the force generating capacity of muscle or as a decreased 
time to task failure or endurance time.26  Muscle fatigue has been extensively investigated in older adults and 
in PCa survivors undergoing radiotherapy using standard electrophysiological techniques.27  Muscle oxidative 
capacity, an index of muscle fatiguability, can be indicated by the 31P-MRS during conscious exercise in 
humans and has been used to successfully study muscle fatigue in chronic disease .28 
 
Muscle biopsies can be used to better understand the pathophysiology behind muscle loss.  There are two 
types of muscle fibers: fast and slow.  Slow muscle fibers are important for postural standing, while fast 
muscle fibers are important for quick movements such as catching oneself while tripping.29  Both are important 
in older patients prone to falls.29   Muscle biopsies have been done in healthy subjects; the procedure is 
minimally invasive and well-tolerated.30 
 
We propose to study to use of HMB plus amino acids in older men with Pca starting ADT.  We hypothesize 
that the use of this nutritional supplementation will decrease the loss of muscle mass and strength that occurs 
when men start ADT.  Use of HMB in men with prostate cancer has not been reported, thus this is a 
completely novel study.  The strength of this project lies in the multidisciplinary approach to evaluation of 
muscle loss and strength in this patient population.  We plan to use geriatric functional assessments, MRI 
measurements and pathologic evaluation of muscle.  We have incorporated a very diverse team including 
medical oncology, geriatrics, radiology, pathology and exercise physiology, with each member of the team 
adding their extensive expertise in their given area. For this reason, we feel that this is a very strong proposal 
which will fundamentally address a promising approach to this important clinical problem.   
 
Preliminary data: 
Abnormal physical performance and frailty in older men on ADT (Bylow).    In a cross-sectional study of 
50 older men (age ≥70) with Pca on long-standing ADT, we found that these men are markedly disabled.31  
50% had abnormal scores on the Vulnerable Elders Score, a geriatric screening tool that identifies patients at 
risk for functional decline.  24% had impairments in Activities of Daily Living (ADLs); 42% had impairments in 
Instrumental Activities of Daily Living (IADLs); 50% had abnormal physical performance measures, and 22% 
reported a fall in the last 3 months. All of these exceed percentages for age- and gender-matched populations. 
  


 
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A second cross-sectional pilot study (Table 1) was performed which compares older men with biochemical 
recurrence of PCa on ADT to controls, defined as men with a history of Pca who are status post definitive local 
therapy with no evidence of disease recurrence.16  In this study, funded by an American Society of Clinical 
Oncology Young Investigator Award (Bylow), we evaluated frailty, physical performance and falls in both 
groups.  Our hypothesis was that those men on ADT would have a higher prevalence of frailty, abnormal 
physical performance and falls than controls.  When using a modified version of Fried’s frailty index,32 
substituting obesity (resulting in lean body mass loss) for weight loss, we found that men on ADT were 
significantly more frail (Table 1).  In addition, men on ADT were significantly more likely to report falling in the 
last six months, possibly due to the muscle loss and weakness they experience on ADT.  
 
 Prostate Cancer-Related Fatigue (CRF) and Radiation Therapy (Ng).27,33,34 12 Pca and 12 healthy control 
subjects participated.  The cancer survivors were tested before and after 6 wks of external beam radiotherapy. 
 The control group was tested at similar times with no intervention.  MVC or strength, muscle endurance, 
muscle oxidative capacity were measured from the ankle dorsiflexor muscles. Oxidative capacity was 
measured using  31P-MRS.  Prior to therapy, both groups were similar in MVC, endurance, sleepiness, and 
depression.  Following radiation therapy, muscle endurance decreased in the cancer group (pre, 556 ± 98s, 
post, 391 ± 51s, mean ± SE, p=0.001), with no change in strength.  In contrast, endurance time in the control 
group increased (pre, 616 ± 112s post, 753 ±160s, p=0.03) after 6 wks, also with no change in strength.  
Preliminary MRS results are consistent with decreased muscle oxidative capacity.  These unique studies also 
demonstrate the feasibility of using magnetic resonance and physiological techniques to assess muscle 
function in men with Pca.  Unlike radiotherapy, we expect significant changes in muscle strength and 
composition with ADT. 
 
 
3. HYPOTHESIS AND OBJECTIVES 
Use of HMB and/or amino acid supplementation in older men with PCa starting on ADT has not been reported. 
 We will prospectively: 1) measure the change in body composition, strength, physical performance, and falls 
in older men with PCa starting on ADT, comparing those who receive HMB + AG versus those who do not, 2) 
evaluate the use of MRI and muscle biopsy to identify changes in muscle composition and muscle fatiguability 
that are known to occur in this patient population.  We will test the hypothesis that HMB + AG can reduce the 
adverse change in body composition and strength/muscle fatiguability that occur when older men with 
Pca are started on ADT.  With data obtained in this study, a larger randomized study will be designed to 
Table 1.  Case-control study comparing frailty/disability for older men on ADT for 
6+ months vs. controls off ADT.  
 
Mean ± SD or % 
p-value 
  
ADT (N = 63) 
Controls  (N = 71) 
 
Age 
72.1± 7.0 
70.5 ± 6.3 
0.21 
Body Mass Index  
 
 
 
     Underweight (< 18) 
0.0 
0.0 
0.04 
     Normal (18.5-25) 
13.5 
20.6 
 
     Overweight (25-30) 
40.4 
58.8 
 
     Obese I & II (30-40) 
40.4 
19.1 
 
     Severely obese (40-45) 
5.8 
1.5 
 
Modified Fried's Frailty, Score (0-
5) 
 
 
 
     0  “Robust” 
34.8 
48.5 
0.02 
     1  “Prefrail” 
32.6 
38.5 
 
     2  “Prefrail” 
23.9 
10.3 
 
     3+ “Frail” 
8.7 
2.9 
 
Fall within past 6 months 
14.3 
2.8 
0.02 
Osteoporosis 
14.3 
4.2 
0.04 
Testosterone (ng/mL) 
21.2 ± 30.9 
377.9 ± 146.9 
< 0.01 


 
5
compare interventions aimed at minimizing the adverse affects that occur with ADT initiation. 
 
Objectives: 
1. Prospectively measure the change in body composition, strength, physical performance measures, and 
falls in older men with PCa starting on ADT, comparing those who receive HMB + AG  versus those 
who do not. 
Hypothesis:  Men who are randomized to receive HMB + AG will experience less lean body mass loss, 
less decrease in strength, less decline in physical performance, and fewer falls than those who do not 
receive HMB + AG. 
 
2. Prospectively measure the fatiguability and muscle size using MRI/Phosphorus MRI spectroscopy (31P-
MRS) in older men with PCa starting on ADT, comparing those who receive HMB + AG versus those 
who do not.  
Hypothesis:  Men who are randomized to receive HMB + AG will experience less muscle fatigue and 
less loss of muscle cross-sectional area than those who do not receive HMB + AG. 
 
3. Prospectively analyze muscle fiber cross sectional area and fiber type using muscle biopsy in a subset 
of men with PCa starting ADT, comparing those who receive HMB + AG versus those who do not. 
Hypothesis:  Men who are randomized to receive HMB+ AG will experience less loss of cross-sectional 
area and less loss of fast type II fibers than those who do not receive HMB + AG. 
 
 
4. SELECTION OF PATIENTS 
 
Prostate cancer patients under the care of an MCW Cancer Center physician will be eligible to participate. 
 
 
Inclusion criteria: 
 
1) Histologically confirmed adenocarcinoma of the prostate 
 
2) Age 60 years or older 
 
3) Patients with asymptomatic or minimally symptomatic PCa for which they are about to start 
androgen deprivation therapy (ADT) per provider recommendation 
• 
Asymptomatic or minimally symptomatic (as judged by treating physician) metastases 
allowed 
• 
Men receiving ADT for localized prostate cancer are allowed 
 
4) Patient able to give informed consent. 
 
  
 
Exclusion criteria: 
 
1) Patient already on ADT 
 
2) Patients who are visiting clinic for a second opinion only 
 
3) Patients with a diagnosis of dementia 
 
4) Patients with a diagnosis of a neuromuscular disorder (i.e. multiple sclerosis) 
 
 
 
 


 
6
 
5. STUDY DESIGN AND STATISTICAL CONSIDERATIONS 
Objective 1:  Prospectively measure the change in body composition, strength, physical performance 
measures, and falls in older men with PCa starting on ADT, comparing those who receive HMB + AG versus 
those who do not.  
 
Rationale:  Older men with prostate cancer who start on ADT experience clinically significant muscle loss and 
weakness as a result of treatment, likely contributing to increase risk of falls and fractures and decreased 
quality of life.  Treatments are needed which counteract the loss of muscle mass and strength caused by ADT. 
 HMB + AG, which decreases protein/muscle breakdown, has been shown to increase lean muscle mass and 
strength in elderly men and women.  It seems plausible that HMB + AG could counteract the muscle loss and 
weakness that men experience as a result of ADT; effectiveness of HMB + AG in men with prostate cancer 
starting ADT has not been studied. 
 
Experimental Design:  We will conduct a prospective cohort pilot study of men age 60 and older with Pca 
who are about to start ADT.   All men will be followed prospectively for 3 months from time of initiation of ADT. 
 Men will be randomized to receive HMB + AG versus no supplement (Figure 2).  Assessments will be 
performed at baseline (before or within 2 weeks of starting ADT) and 3 months (Table 2).  Adherence to HMB 
will be assessed by patient diaries.  Functional assessments and basic strength measurements will be 
performed at baseline and 3 months.  These will include the Short Physical Performance Battery (SPPB), a 
validated measure which evaluates balance, gait, strength, and endurance and has been shown to predictive 
of morbidity and mortality at 4 years.35,36 Hand dynamometer (grip strength, predictive of morbidity and 
mortality on older patients) and 3 month history of falls will also be assessed.  Physical activity will be 
measured with tri-axial accelerometers (Actigraph,  Pensacola FL) that persons will wear on a belt around the 
waist for 7-days.37  This has been used previously in men with prostate cancer.27  Body composition will be 
measured with Dual-emission X-ray absorptiometry (DXA) scan at baseline and 3 months.  Muscle strength 
will be measured with non-magnetic force transducers and composition will be measured with MRI at baseline 
and 3 months (SA2).  Muscle biopsies will be done on a subset of patients who agree to the procedure (SA3). 
 
Setting: The patients will be recruited from Oncology and Urology clinics at Froedtert Hospital.  PCa patients in 
the clinics who consent to participate in this study will do physical performance testing at each assessment.  A 
trained research assistant (RA) will administer testing and enter data into a secure database.   Serious 
adverse events and study progress for this investigator initiated trial will be monitored by Kathryn Bylow, MD 
per NCI CCSG guidelines.  Recruitment: Based on the number of patients currently seen in these clinics, 
approximately 2-3 patients will be seen a week who are eligible for this study.  A total of 80 patients (40 in 
each arm) will be enrolled in this pilot study. 
 
 
 
 
 
 
ENROLLED 
Men with Pca 
Age≥60, about to start on ADT 
Anticipate n = 80
CONTROLS 
Standard of care:  ADT only 
n = 40 
HMB GROUP 
Treatment arm:  ADT + HMB + AG 
n = 40 
Figure 2. Trial design 


 
7
 
 
 
 
 
 
 
 
 
 
 
 
Data Analysis: 
Study design:  The trial will be conducted in two phases, with 40 patients recruited for both phases. After the 
first 40 patients have been evaluated, a two-sample one-sided t-test comparing the mean lean body mass loss 
will be conducted. If the one-sided p-value is equal or less than 0.0088, the trial will be stopped for efficacy. If 
the p-value exceeds 0.3, the trial will be stopped for futility. In all other cases the trial will proceed to the next 
phase. At the end of the second phase a two-sample one-sided t-test comparing the mean lean body mass 
loss in the two groups will be conducted at a 5% significance level.   Randomization:  Randomization will be 
stratified by exercise status to ensure almost equal representation of both strata in both treatment groups.  A 
block-size of 8 will be used, that is among each 8 consecutive patients exactly 4 will receive each treatment.  
Due to the presence of strata this blocking will not ensure exactly equal group size, however compared to un-
blocked randomization it will keep the group-size difference lower.  Sample size considerations:  The study 
was powered to detect a smaller lean body mass loss by 0.8 kg in the treated group using a one-sided two-
sample t-test at a 5% significance level. This effect size corresponds to approximately 50% of the expected 
lean body mass loss in the control group, and is similar to the effect achieved by an exercise intervention.38 
Based on literature review the standard deviation of within-person lean body mass change was assumed to be 
1.4kg.38,39 The following table shows the power of the study and the probability of early stopping for 
efficacy/futility with the planned total sample size of 40 subjects per group and one interim analysis after 20 
patients. The values are based on 10,000 simulation runs. 
 
Difference in lean body 
mass loss, kg 
Probability of early stopping 
for efficacy 
Probability of early stopping 
for futility 
Overall 
power 
0 
0.9% 
70.3% 
4.7% 
0.4 
6.5% 
35.4% 
33.7% 
0.8 
26.4% 
10% 
78.0% 
1.2 
59.5% 
1.5% 
97.5% 
1.6 
86.8% 
0.1% 
99.8% 
 
Statistical analysis plan: As described in the study design, the primary outcome of within-person lean body 
mass change will be analyzed using a one-sided two-sample t-test. This test will be conducted at a 0.88% 
significance level after 20 patients have been evaluated in both arms, and, if the study proceeds to the end, at 
a 5% significance level after 40 patients have been evaluated in both arms. The secondary outcomes will be 
evaluated using a t-test or Wilcoxon rank-sum test as appropriate. 
Anticipated Results/Interpretation:  We anticipate that body composition will be better preserved in the 
supplemented group after initiation of ADT.  In addition, we expect less functional limitations to mobility in the 
supplemented group as indicated by greater physical activity as measured by accelerometry.  Further we 
expect physical activity to be positively related to muscle strength and endurance. 
 
Objective 2:  Prospectively measure the fatiguability and muscle size using MRI/Phosphorus MRI 
spectroscopy (31P-MRS) in older men with PCa starting on ADT, comparing those who receive HMB + AG 
versus those who do not. 
 
 
Table 2:  Measures performed over time per group 
 
Baseline 
3 months 
SPPB 
HD 
falls 
MRI 
Biopsy 
SPPB 
HD 
falls 
MRI 
Biopsy 
Control 
X 
X* 
X* 
X 
X* 
X* 
HMB 
X 
X* 
X* 
X 
X* 
X* 
SPPB:  Short Physical Performance Battery; HD:  hand 
dynamometer; 
* MRI and Biopsy to be done on subset of sample 


 
8
Rationale:  Fatigue is highly prevalent in men with PCa undergoing ADT and can affect QOL.  Muscle fatigue 
could be due decreased oxidative capacity as a primary or secondary effect of the cancer or its treatment.  
Fatigue could also result from muscle weakness or loss of strength.  The later could occur when a smaller 
amount of muscle has to accomplish the same amount of work as that of a larger amount.  31P- MRS is a non 
invasive in vivo technique which can be used to study phosphorus energy metabolites in conscious humans 
during exercise.  As such, it can help to delineate the causes of muscle fatigue in PCa with ADT.  We expect 
both to play a role.  HMB + AG has been shown to increase muscle strength in older patients.  It stands to 
reason that muscle strength and fatiguability would improve in older men with prostate cancer on ADT who 
receive HMB + AG. 
 
Experimental Design:  A subset of consenting patients (estimated 20 per group) will be assessed at time 
increments as outlined above.  Cross sectional area of quadriceps muscle will be assessed using MRI.  
Muscle fatiguability will be measured as time to task failure (i.e. endurance and PCr recovery) using  31P-MRS 
at baseline and 3 months. 
   
Data Anlaysis:   Exploratory MRI studies will be conducted on the first 40 consenting patients. This sample 
size will provide an 80% power to detect large effects with effect size of 0.9 or above at a two-sided 5% 
significance level. 
 
Anticipated Results/Interpretation:  We expect lean cross sectional area and therefore strength to be 
preserved or enhance in the HMG+AG  group.   We also expect endurance and muscle oxidative capacity to 
be preserved or enhanced in the HMG+AG group.  
 
Objective 3:  Prospectively analyze  muscle fiber cross sectional area and fiber type using muscle biopsy in a 
subset of men with PCa starting ADT, comparing those who receive HMB + AG versus those who do not. 
 
Rationale:  Studies in older patients indicate that HMB, when given with amino acids, helps to maintain 
protein synthesis and slow muscle breakdown.  ADT is known to cause accelerated loss of lean muscle mass. 
 HMB + AG, when given to men starting androgen deprivation therapy, may prevent loss of lean muscle mass. 
 Biopsy of muscle will definitively show cross sectional area and fiber type (fast versus slow) in this patient 
population.  A better understanding of changes in fiber type will clarify the pathophysiology behind ADT toxicity 
and the potential mechanism of action of HMB + AG. 
 
Experimental Design:  A subset of patients will undergo muscle biopsy (vastus lateralis) at baseline and 3 
months.   We will compare pre-ADT versus post-ADT muscle biopsy for fiber type composition and fiber type 
cross sectional area.   Muscle fiber type histochemical staining will be done as follows:  1) Biopsies will be 
quick frozen in isopentane cooled with liquid nitrogen, 2) Store frozen pre sample at -80C until get individual’s 
post sample, 3) Cut 10 micron cross sections of pre and post and collect sections on same slide; process 
together in same incubation medium to prevent variation in day to day composition of the incubation 
conditions, 4) Incubate slides for histochemical myofibrillar ATPase activity using acid-preincubation and 
alkaline-preincubation to accentuate fast and slow fiber subtypes,40 5) Based on muscle fiber staining 
intensities, quantified with MetaMorph computerized optical density readings, segregate fibers into fast and 
slow fiber types and determine the percentages of each type. For each fiber, measure its cross sectional area 
using MetaMorph digitizing planimetry.  A separate consent form will be provided to consent for this procedure. 
 We will compare those who receive HMB + AG to those who do not.   
 
Data Analysis:   Exploratory muscle biopsies will be conducted on the first 10 consenting patients. This 
sample size will provide an 80% power to detect large effects with effect size of 0.9 or above at a two-sided 
5% significance level. 
 
Anticipated Results/Interpretation:  The percentage of fast fibers will decrease post ADT. Slow fibers will 
transform from slow to fast (shift in gene expression from slow myosin to fast myosin).  The cross sectional 
areas of fast and slow fibers will decrease post ADT.   ADT causes decreased synthesis of contractile proteins 
so muscle fibers atrophy.  The post ADT shift in slow to fast fibers and fiber atrophy will cause the individual to 


 
9
exhibit greater muscle fatigue and weakness. The fast fibers are more fatigable than slow fibers. Slow fibers 
are normally utilized to maintain posture, against gravity. They can contract for long periods without fatiguing. 
Fast fibers are fatigable so the person is likely to have difficulty maintaining posture. The reduced cross 
sectional areas of both fiber types represent a decrease in contractile proteins and less force output of the 
muscle. The individual is more likely to fall.  HMB + AG treatment will prevent the post ADT shift from slow to 
fast fiber transformation and prevent muscle fiber atrophy.  HMB individuals will have less fatiguability, 
stronger and less likely to fall. 
 
 
6. RISKS TO PATIENTS 
 
HMB + AG:   Based on prior studies, those patients who receive HMB+AG vs placebo may have a higher 
incidence of dry scalp and heartburn.  No other significant adverse reactions have been reported. 
 
Functional assessments:  Functional assessments are quite simple and have been shown to be very safe 
in geriatric patient population.  It is possible that patient could trip during balance/walking test and injure 
themselves, although risk is very small. 
 
Imaging:  It is possible that patients may experience some anxiety as a result of imaging, although chance 
of this is minimal.  Patient may experience mild discomfort as a result of lying flat for a period of time on 
hard surface for both DXA scan and MRI.  As we are just imaging lower extremity, patient’s head will be 
able to remain outside of tube for MRI so claustrophobia should not be an issue. 
 
Muscle Biopsy:  Patients may experience some pain due to muscle biospsy.  There is also a small chance 
of bleeding or infection related to this procedure.  Patients are not required to participate in this portion of 
the study. 
  
Confidentiality risks: Though we will make every effort to maintain participant confidentiality, the loss of 
confidentiality is a risk.  
 
Patient Costs: There will be no additional cost to the patient, as the cost of 31P-MRS, DXA scan, functional 
assessments and immunohistochemical stains will be covered by a MCW Cancer Center grant.  The 
patient and/or their insurance carrier will be responsible for all charges relating to standard of care labs, 
doctor visits, and imaging deemed necessary by patient’s provider to assess status of prostate cancer. 
 
 
 
7. ADVERSE EVENT REPORTING REQUIREMENTS 
  
Any adverse events will be reported based on the NCI Common Toxicity Criteria (CTC) version 3.0. SAE’s 
that occur will be reported to the IRB following the IRB Reporting Guidelines. Adverse events (AE’s) or 
Significant adverse events (SAE’s) will be collected until 30 days after the completion of study (4 months 
from enrollment).  
 
 
8. DATA SAFETY MONITORING COMMITTEE (DSMC) REPORTING 
This study will be reviewed by the Medical College of Wisconsin Cancer Center Data Safety Monitoring 
Committee (MCW CC DSMC). A summary of the MCW CC DSMC activities are as follows:  
• 
Review the clinical trial for data integrity and safety  
• 
Review all unexpected grade 3, and all grade 4, and 5 adverse events, as well as any others requiring 
expedited reporting as defined in this protocol. (Grades 4 & 5 events must be reported to the DSMC 
within 5 calendar days of study staff’s knowledge.) Review all DSM reports  
• 
Submit a summary of any recommendations related to study conduct  
• 
Terminate the study if deemed unsafe for patients  


 
10 
 
A copy of the MCW CC Data and Safety Monitoring Plan and membership roster will be maintained in the 
study research file and updated as membership changes. The committee will review reports from the study 
PI twice annually (or more frequently if needed) and provide recommendations on trial continuation, 
suspension or termination as necessary.  
 
Any available DSMC letters will be submitted to the IRB of record as required. 
 
 
9. STORAGE OF RESEARCH SPECIMENS 
 
Muscle biopsies will be stored until follow up biopsy completed 3 months later for each patient.  Details of 
this process outlined in Objective 3 above.  These biopsies will be de-identified by Dr. Riley, and a private 
patient identification number will be used on these slides.  The key for this identification system will reside 
on Dr. Riley’s password protected computer.  Those de-identified specimens will be stored in the lab of Dr. 
Riley.  The prepared slides from the biopsies and the protected health information (PHI) may be stored up 
to 10 years after the end of the study.   
 
  
 10.  REFERENCES 
 
1. 
Ries LAG, Harkins D, Krapcho M, et. a. SEER Cancer Statistics Review, 1975-2003. In. Bethesda, MD: 
National Cancer Institute; 2006. 
2. 
SEER Medicare Database (http://seer.cancer.gov/statfacts/html/prost.html). In; 2010. 
3. 
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of 
progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7. 
4. 
Newschaffer CJ, Otani K, McDonald MK, Penberthy LT. Causes of death in elderly prostate cancer 
patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 2000;92:613-21. 
5. 
Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 
2003;61:32-8. 
6. 
Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat 
content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent 
bone metastases given androgen deprivation therapy. J Urol 2002;167:2361-7; discussion 7. 
7. 
Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen 
deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002;87:599-603. 
8. 
Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body 
composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001;86:4261-
7. 
9. 
Basaria S, Lieb J, 2nd, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate 
cancer patients. Clin Endocrinol (Oxf) 2002;56:779-86. 
10. 
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for 
prostate cancer. N Engl J Med 2005;352:154-64. 
11. 
Potosky AL KK, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS et al. Quality-of-life outcomes after 
primary androgen deprivation therapy: results from the Prostate Cancer OUtcomes STudy. J Clin ONcol 
2001;19:3750-57. 
12. 
Lubeck DP GG, Carroll PR. The effect of androgen deprivation therapy on health-related quality of life 
in men with prostate cancer. Urology 2001;58:94-100. 
13. 
Schroder FH. Endocrine treatment of prostate cancer: recent develpments and the future. Part I: 
maximal androgen bleckage, early vs. delayed endocrine treatment and side-effects. BJU Int 1999;83:220. 
14. 
Iverson P. Quality of life issues relating to endorcrine treatment options. Eur Urol 1999;36 (suppl.):20. 
15. 
Bylow K, Mohile SG, Stadler WM, Dale W. Does androgen-deprivation therapy accelerate the 
development of frailty in older men with prostate cancer?: a conceptual review. Cancer 2007. 
16. 
Bylow K, Hemmerich J, Mohile SG, Stadler WM, Sajid S, Dale W. Obese frailty, physical performance 
deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation 


 
11 
therapy: a case-control study. Urology 2010:Accepted for publication, in press. 
17. 
Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-
releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005;103:1615-24. 
18. 
Lexell J, Taylor CC, Sjostrom M. What is the cause of the ageing atrophy? Total number, size and 
proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men. J 
Neurol Sci 1988;84:275-94. 
19. 
Tzankoff SP, Norris AH. Effect of muscle mass decrease on age-related BMR changes. J Appl Physiol 
1977;43:1001-6. 
20. 
Mauras N, Hayes V, Welch S, et al. Testosterone deficiency in young men: marked alterations in whole 
body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 1998;83:1886-92. 
21. 
Baier S, Johannsen D, Abumrad N, Rathmacher JA, Nissen S, Flakoll P. Year-long changes in protein 
metabolism in elderly men and women supplemented with a nutrition cocktail of beta-hydroxy-beta-
methylbutyrate (HMB), L-arginine, and L-lysine. JPEN J Parenter Enteral Nutr 2009;33:71-82. 
22. 
Flakoll P, Sharp R, Baier S, Levenhagen D, Carr C, Nissen S. Effect of beta-hydroxy-beta-
methylbutyrate, arginine, and lysine supplementation on strength, functionality, body composition, and protein 
metabolism in elderly women. Nutrition 2004;20:445-51. 
23. 
May PE, Barber A, D'Olimpio JT, Hourihane A, Abumrad NN. Reversal of cancer-related wasting using 
oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am J 
Surg 2002;183:471-9. 
24. 
Kent-Braun JA, Ng AV. Specific strength and voluntary muscle activation in young and elderly women 
and men. J Appl Physiol 1999;87:22-9. 
25. 
Kent-Braun JA, Ng AV, Young K. Skeletal muscle contractile and noncontractile components in young 
and older women and men. J Appl Physiol 2000;88:662-8. 
26. 
Bigland-Ritchie B, Johansson R, Lippold OC, Woods JJ. Contractile speed and EMG changes during 
fatigue of sustained maximal voluntary contractions. J Neurophysiol 1983;50:313-24. 
27. 
Alt C, Gore E, Montagnini M, Ng AV. Muscle Endurance, Cancer-Related Fatigue, and Radiotherapy in 
Prostate Cancer Survivors. Muscle Nerve 2010:Accepted for publication, in press. 
28. 
Kent-Braun JA, Sharma KR, Miller RG, Weiner MW. Postexercise phosphocreatine resynthesis is 
slowed in multiple sclerosis. Muscle Nerve 1994;17:835-41. 
29. 
Lee WS, Cheung WH, Qin L, Tang N, Leung KS. Age-associated decrease of type IIA/B human 
skeletal muscle fibers. Clin Orthop Relat Res 2006;450:231-7. 
30. 
Fitts RH, Trappe SW, Costill DL, et al. Prolonged space flight-induced alterations in the structure and 
function of human skeletal muscle fibres. J Physiol;588:3567-92. 
31. 
Bylow K, Dale W, Mustian K, et al. Falls and physical performance deficits in older patients with 
prostate cancer undergoing androgen deprivation therapy. Urology 2008;72:422-7. 
32. 
Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A 
Biol Sci Med Sci 2001;56:M146-56. 
33. 
Ng AV, Alt CA, Gore E. Mechanisms of Fatigue in Cancer Survivors. Med Sci Sports Exerc 
2006;38:S38. 
34. 
Ng AV, Alt CA, Gore E. Mechanisms of Cancer-Related Fatigue. In: Feuerstein M, ed. The Handbook 
of Cancer Survivorship: Springer; 2007. 
35. 
Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons 
over the age of 70 years as a predictor of subsequent disability. N Engl J Med 1995;332:556-61. 
36. 
Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower 
extremity function: association with self-reported disability and prediction of mortality and nursing home 
admission. J Gerontol 1994;49:M85-94. 
37. 
Montoye HJ, Washburn R, Servais S, Ertl A, Webster JG, Nagle FJ. Estimation of energy expenditure 
by a portable accelerometer. Med Sci Sports Exerc 1983;15:403-7. 
38. 
Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise 
program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without 
bone metastases: a randomized controlled trial. J Clin Oncol;28:340-7. 
39. 
Haseen F, Murray LJ, Cardwell CR, O'Sullivan JM, Cantwell MM. The effect of androgen deprivation 
therapy on body composition in men with prostate cancer: systematic review and meta-analysis. J Cancer 
Surviv;4:128-39. 


 
12 
40. 
Huckstorf BL, Slocum GR, Bain JL, et al. Effects of hindlimb unloading on neuromuscular development 
of neonatal rats. Brain Res Dev Brain Res 2000;119:169-78. 
 

ICF_001.pdf: 
Medical College of Wisconsin & Froedtert Hospital  
 
 
Informed Consent for Research 
Template A - Version: February 25, 2011 
 
IRB Protocol Number: PRO00016781 
IRB Approval Period: 10/01/2018 – 09/30/2019  
MCW Consent v. 8/14/15 
 
Page 1 of 7 
EFFECTIVE 
 
10/01/2018 
 
MCW/FH IRB
 
Medical College of Wisconsin and Froedtert Hospital 
CONSENT TO PARTICIPATE IN RESEARCH 
 
Name of Study Subject: ____________________________ 
 
USE OF ß-HYDROXY-ß-METHYLBUTYRATE (HMB) TO COUNTERACT LOSS OF 
MUSCLE MASS AND STRENGTH IN OLDER MEN WITH PROSTATE CANCER 
STARTED ON ANDROGEN DEPRIVATION THERAPY (ADT) 
 
Kathryn Bylow, MD 
Froedtert & Medical College of Wisconsin 
Division of Hematology and Oncology 
9200 W. Wisconsin Avenue 
Milwaukee WI 53226 
414-805-6800 
 
You are invited to take part in this research study. This form tells you why this research 
study is being done, what will happen in the research study, possible risks and benefits 
to you, your choices, and other important information. If there is anything that you do not 
understand, please ask questions. Then you can decide if you want to join this study or 
not.   
 
A1. INTRODUCTION – WHY ARE WE ASKING YOU ABOUT THIS STUDY? 
You are being invited to participate in this research study because you are age 60 or 
older with prostate cancer and you will be starting on androgen deprivation therapy 
(ADT). ADT is a standard treatment for prostate cancer. 
 
A total of about 80 people are expected to participate in this study at the Medical 
College of Wisconsin/Froedtert Hospital. 
 
The Director of the study is Kathryn Bylow, MD in the Department of Hematology and    
Oncology. A study team works with Dr. Bylow. You can ask who these people are.  
 
Dr. Bylow has received funding for this study through a Froedtert & Medical College of 
Wisconsin Cancer Center Grant. 
 
A2. DO I HAVE TO BE IN THIS STUDY? 
You can decide whether to take part in this study or not. You are free to say yes or no. If 
you say no, your regular medical care will not change. Even if you join this study, you do 
not have to stay in it. You may stop at any time.  
 
A research study is different from routine medical care in three ways: 1) there are extra 
risks that we will tell you about in this form; 2) you may have some extra medical tests 
and visits; 3) the study procedures, tests and visits follow a set plan that must be kept. 


Medical College of Wisconsin & Froedtert Hospital  
 
 
Informed Consent for Research 
Template A - Version: February 25, 2011 
 
IRB Protocol Number: PRO00016781 
IRB Approval Period: 10/01/2018 – 09/30/2019  
MCW Consent v. 8/14/15 
 
Page 2 of 7 
EFFECTIVE 
 
10/01/2018 
 
MCW/FH IRB
 
A3. WHY IS THIS RESEARCH STUDY BEING DONE? 
The purpose of this study is to evaluate if the nutritional supplement ß-Hydroxy-ß-
Methylbutyrate (HMB) plus the amino acids arginine and glutamine (AG) will help 
decrease the loss of muscle size and strength that occurs with the treatment of prostate 
cancer. HMB and amino acids work together to increase muscle and strength. 
   
B1. WHAT WILL HAPPEN IF I TAKE PART IN THE STUDY?   
 
Research study groups 
You will be randomized into one of the two study groups. One group will receive 
standard of care androgen deprivation therapy (ADT) with the nutritional supplement 
HMB + AG amino acids (1 packet contains 1.2 g of the amino acid metabolite HMB, 7 g 
of the amino acid arginine, and 7 g of the amino acid glutamine) and one group will 
receive standard of care ADT. Randomization means that you are put into a group by 
chance. It is like flipping a coin.  You will have an equal chance of being placed in either 
group. Neither you nor the study doctor can choose what group you will be in.  
 
Summary of Study Procedures: 
 
 
HMB+AG: If you are randomized to receive HMB+AG, you will take 1 packet of 
the nutritional supplement 2 time(s) per day. The nutritional supplement should 
be mixed with 8-10 fluid ounces of water or other liquid such as fruit juice. You 
can also mix the nutritional supplement in yogurt or applesauce. It should not be 
mixed with very hot or very cold liquid. You will be asked to keep a diary to 
record the date, number of packets taken, and time taken.  You will be asked to 
return the completed diary and empty HMB + AG packets at your 3 month visit. 
 
The following procedures will be done at the start of the study and 3 months after the 
start of the study: 
 
 Functional assessments: These assessments include hand strength, tests of 
balance, walking ability and speed and take about 5-10 minutes to complete. 
These assessments will be done by a member of the research team. 
 
 Physical Activity Measurement:  You will be asked to wear an activity monitor 
for 5-7 days.  This is a small portable device about the size of a pager that 
records movements.  It is to be worn around the waist.  You will also be asked to 
keep a simple diary of your physical activities. After you have completed the 
monitoring you can return the instrument to us on your next training day.  You will 
not have to wear the device to sleep, while bathing, or for formal gatherings. 
 
 
 


Medical College of Wisconsin & Froedtert Hospital  
 
 
Informed Consent for Research 
Template A - Version: February 25, 2011 
 
IRB Protocol Number: PRO00016781 
IRB Approval Period: 10/01/2018 – 09/30/2019  
MCW Consent v. 8/14/15 
 
Page 3 of 7 
EFFECTIVE 
 
10/01/2018 
 
MCW/FH IRB
 Dual-emission X-ray absorptiometry (DXA) scan: A DXA scan is a painless test 
that measures the density of bones. Generally, the denser your bones are the 
stronger they are, and the less likely they are to break. DXA scans help find out 
whether you have osteoporosis or are at risk of developing it. They can also be 
used to detect other bone disorders and conditions, and to monitor the relative 
amounts of body fat and muscle in your body. Men who are getting treated for 
prostate cancer are at a risk of loss of bone strength. You will have 2 DXA scans 
during this study – once at the start of the study and once 3 months after the start 
of the study. You will be asked to lie down on a scan table and remain 
motionless. A scanner will pass over you.  The procedure will take a total of 10-
15 minutes to complete. 
 
B2. HOW LONG WILL I BE IN THE STUDY? 
You will be in this research study for about three months. 
 
B3. CAN I STOP BEING IN THE STUDY?   
You are free to withdraw from the study at any time. If you leave, your regular medical 
care will not change. If you are thinking about leaving, please tell the study doctor. You 
will be asked to return your diary any unused nutritional supplements or empty 
nutritional supplement containers. 
 
The study doctor may take you out of this study at any time. This would happen if: 
 
They think it is in your best interest. 
 
You do not follow the study rules. 
 
The whole study is stopped. 
If this happens, the study doctor will tell you. 
 
B4. ARE THERE ANY SPECIAL INSTRUCTIONS WHILE I AM IN THE STUDY?  
If you are randomized to receive HMB+AG, please tell all of your healthcare providers 
that you are taking this nutritional supplement. 
 
C1. WHAT HEALTH RISKS OR PROBLEMS CAN I EXPECT FROM THE STUDY? 
There are risks to taking part in any research study. There also may be problems (side 
effects) we do not know about yet, the HMB+AG or how it combines with other drugs 
you are taking. If we learn about new important side effects, we will tell you.  
 
We watch everyone in the study for problems (side effects). You need to tell the study 
doctor or a member of the study team immediately if you experience any 
problems, side effects, or changes in your health.   
 
C2. RISKS OF HMB+AG 
HMB+AG may cause problems (side effects).  Side effects may be mild or very serious.  
Some can last a long time or never go away.   
 
 


Medical College of Wisconsin & Froedtert Hospital  
 
 
Informed Consent for Research 
Template A - Version: February 25, 2011 
 
IRB Protocol Number: PRO00016781 
IRB Approval Period: 10/01/2018 – 09/30/2019  
MCW Consent v. 8/14/15 
 
Page 4 of 7 
EFFECTIVE 
 
10/01/2018 
 
MCW/FH IRB
Rare side effects (<10%) 
Based on prior studies, those patients who receive HMG+AG vs placebo may have a 
higher incidence of dry scalp and heartburn. No other significant side effects have been 
reported.  
 
C3. OTHER RISKS OF THIS RESEARCH STUDY 
Other procedures that are part of the study also involve some risks: 
 
Functional assessments 
Functional assessments have been shown to be very safe in the geriatric patient 
population.  It is possible that you could trip during the balance/walking test and injure 
yourself, although the risk is very small. A member of the research team will be standing 
with you at all times for safety.   
 
Imaging 
The DXA scan uses low level x-rays for imaging. It is possible that you may experience 
some anxiety as a result of imaging, although chance of this is minimal.  Patients may 
experience mild discomfort as a result of lying flat for a period of time on hard surface 
for both DXA scans. 
 
Confidentiality 
Another risk may be loss of confidentiality. Every effort will be made to keep your study 
records confidential but we cannot guarantee it. Depending on the kind of information 
being collected, if your study information were accidentally seen, it might be used in a 
way that could embarrass you or affect your ability to get insurance. If you have 
questions, you can talk to the study director about whether this could apply to you.  
 
C5. ARE THERE ANY BENEFITS TO TAKING PART IN THE STUDY? 
We don’t know if this study will help you. Your condition may get better but it could stay 
the same or even get worse. We hope the information from this study will help us 
develop better treatments for prostate cancer. 
 
D1. ARE THERE ANY COSTS TO BEING IN THE STUDY? 
Some of the medical care that you will receive in this study is considered routine care 
for your condition and would be recommended whether you join the study or not.  Costs 
for routine care such as physical exams and the standard treatment with Androgen 
Deprivation Therapy will be billed to you or your insurance carrier.  Activities / costs that 
are part of the study will not be billed to you or your insurance company. These are the 
cost of the HMB+AG and DXA scans. Some insurers will not pay for drugs, tests or 
hospitalization that are part of research studies, so check with your insurer before you 
join this study. If you have questions regarding study costs, please contact Dr. Bylow. 
 
D2. WILL I BE PAID FOR PARTICIPATING IN THE STUDY? 
You will not be paid for taking part in this study. 
 


Medical College of Wisconsin & Froedtert Hospital  
 
 
Informed Consent for Research 
Template A - Version: February 25, 2011 
 
IRB Protocol Number: PRO00016781 
IRB Approval Period: 10/01/2018 – 09/30/2019  
MCW Consent v. 8/14/15 
 
Page 5 of 7 
EFFECTIVE 
 
10/01/2018 
 
MCW/FH IRB
D3. WHAT OTHER HEALTHCARE CHOICES DO I HAVE? 
You do not have to join this study. You are free to say yes or no. If you do not join this 
study, your doctor can discuss other healthcare choices with you.  
 
D4. WILL I BE GIVEN NEW INFORMATION ABOUT THE STUDY? 
If we learn any important new information about the supplement HMG+AG that might 
change your mind about being in the study, we will tell you about it right away.  You can 
then decide if you want to stay in the study. 
 
D5. WHAT HAPPENS IF I AM HARMED BECAUSE I TOOK PART IN THE STUDY?  
No funds have been set aside to pay any costs if you become ill or are harmed because 
of this study. If you think that you have become ill or were harmed because of this 
study, let the study doctors know right away by calling 414-805-6800.  By signing this 
form, you do not give up your right to seek payment for harm you receive while 
participating in this study. 
 
D6. WHO CAN ANSWER MY QUESTIONS ABOUT THE STUDY? 
 
If you have more questions about this study at any time, you can call Dr. Bylow at 
414-805-6800. 
 
If you have questions about your rights as a study participant, want to report any 
problems or complaints, obtain information about the study, or offer input, you can 
call the MCW/Froedtert Hospital Research Subject Advocate at 414-456-8844. 
 
E. PERMISSION TO COLLECT, USE AND SHARE HEALTH INFORMATION 
 
E1. What health information will be collected and used for this study? 
To do this research study, we need your permission to collect and use some of your 
health information, or you cannot be in the study. This information may come from 
questions we ask, forms we ask you to fill out, or your medical record, as described 
below. We will only collect and use information needed for the study.  
 
The health information to be collected and used for this study is:  
 Hospital/Medical Records 
 Physician/Clinic Reports 
 Lab and/or Pathology Reports 
 Radiological Reports 
 Biological Samples 
 Data Previously Collected for Clinical Purposes 
 
E2. Who will see the health information collected for this study? 
The only MCW/Froedtert Hospital employees allowed to handle your health information 
are those on the study team, those on the Institutional Review Board (IRB) and those 
who check on the research activities to make sure the hospital’s rules are followed. 
 


Medical College of Wisconsin & Froedtert Hospital  
 
 
Informed Consent for Research 
Template A - Version: February 25, 2011 
 
IRB Protocol Number: PRO00016781 
IRB Approval Period: 10/01/2018 – 09/30/2019  
MCW Consent v. 8/14/15 
 
Page 6 of 7 
EFFECTIVE 
 
10/01/2018 
 
MCW/FH IRB
We may record your research information, including results of tests and procedures 
done for research, in your Froedtert Hospital and/or Medical College of Wisconsin 
medical record.  As a result, this research information may be seen by people allowed 
to see your medical records for healthcare operations or treatment, by those you allow 
to see your medical records by giving written permission, and by others when required 
by law. 
 
We will not use your personal health information for a different study without your 
permission or the permission of a hospital research review board (IRB). Once all 
personal identification is removed, the information might be used or released for other 
purposes without asking you. Results of the study may be presented in public talks or 
written articles, but no information will be presented that identifies you. 
  
E3. What are the risks of sharing this health information? 
One risk of taking part in a research study is that more people will handle your personal 
health information collected for this study. The study team will make every effort to 
protect the information and keep it confidential, but it is possible that an unauthorized 
person might see it. Depending on the kind of information being collected, it might be 
used in a way that could embarrass you or affect your ability to get insurance. If you 
have questions, you can talk to the study doctor about whether this could apply to you.  
 
E4. How long will you keep the health information for this study? 
If you sign this form, we plan to keep your information without an end date in case we 
need to check it again for this study. 
 
E5. Can I cancel my permission to share this health information? 
If you change your mind later and do not want us to collect or share your health 
information, you need to send a letter to Dr. Bylow at Froedtert & Medical College of 
Wisconsin, Division of Hematology and Oncology, 9200 W. Wisconsin Avenue, 
Milwaukee WI 53226. The letter must say that you have changed your mind and do not 
want the researcher to collect and share your health information. At that time, we may 
decide that you cannot continue to be part of the study. We may still use the information 
we have already collected.  
FOR MORE INFORMATION ABOUT THE STUDY 
You can get more information about this study on the Federal government’s web site for 
clinical trials, at http://www.ClinicalTrials.gov (trial number NCT01607879) as required 
by U.S. Law, or by asking the study team for a printed copy. This website will not 
include information that can identify you. At most, the website will include a summary of 
the results. You may search this website at any time.    
 
 
 


Medical College of Wisconsin & Froedtert Hospital  
 
 
Informed Consent for Research 
Template A - Version: February 25, 2011 
 
IRB Protocol Number: PRO00016781 
IRB Approval Period: 10/01/2018 – 09/30/2019  
MCW Consent v. 8/14/15 
 
Page 7 of 7 
EFFECTIVE 
 
10/01/2018 
 
MCW/FH IRB
 
CONSENT TO PARTICIPATE IN THE STUDY 
 
By signing my name below, I confirm the following: 
 I have read (or had read to me) this entire consent document.  All of my questions 
have been answered to my satisfaction. 
 The study’s purpose, procedures, risks and possible benefits have been explained to 
me.   
 I agree to let the study team use and share the health information and other 
information gathered for this study. 
 I voluntarily agree to participate in this research study.  I agree to follow the study 
procedures as directed.  I have been told that I can stop at any time. 
 
IMPORTANT: You will receive a signed and dated copy of this consent form.  Please 
keep it where you can find it easily.  It will help you remember what we discussed today. 
 
 
 
 
 
Subject's Name please print  
Subject's Signature 
Date    
 
 
 
Name of Legally Authorized 
Representative (if applicable)  
please print  
Signature of Legally Authorized 
Representative 
Date 
 
 
 
Name of Witness (if applicable) please 
print  (for short form consent process, or 
consent of blind or illiterate subject) 
Signature of Witness 
 
Date 
 
 
 
* Name of person discussing/ 
obtaining consent please print  
Signature of person 
discussing/obtaining consent 
Date 
* A member of the study team trained and authorized by the Principal Investigator to act on her/his behalf 
in obtaining informed consent according to the protocol.  In all research study protocols the Principal 
Investigator is responsible and accountable for the study.